The recent approval of several swine flu vaccines by top pharmaceutical companies will benefit industries associated with the swine flu virus.
Recent approval of swine flu vaccine’s by top pharmaceutical companies GlaxoSmithKline (GSK), Novartis (NVS) and Baxter International (BAX) to help ease influenza pandemic.
With a micro-injection influenza vaccine currently in phase II of development, Sanofi Adventis has the capability to develop the first swine flu vaccine. To supply the new swine flu virus at a global scale, companies like Sanofi Aventis may join efforts with other top pharmaceutical companies like AVI Biopharma (AVII), Pure Bioscience (PURE), Roche (RHHBY) and Antigenics (AGEN).
The effects of Tamiflu and Relenza in young children under 12 have proven to be uneffective. All it seems to do is delaying the swine flu symptoms by 1 day, so the child can go to school and infect other children. The swine flu antiviral medication is only effective in 8% of the swine flu cases; if you want to cure a swine flu case of a child 12, you would have to supply the swine flu antiviral to up to 13 children.

